CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,314,313 | -28.1% | 2,900,335 | +4.8% | 0.00% | -20.0% |
| Q2 2023 | $88,003,526 | +15.0% | 2,768,277 | -11.8% | 0.01% | +25.0% |
| Q1 2023 | $76,525,723 | -64.6% | 3,137,586 | -54.2% | 0.00% | -33.3% |
| Q4 2022 | $215,999,798 | +181.1% | 6,848,440 | +151.8% | 0.01% | +20.0% |
| Q3 2022 | $76,847,000 | +20.4% | 2,719,272 | +12.6% | 0.01% | +25.0% |
| Q2 2022 | $63,839,000 | -15.7% | 2,414,474 | +11.7% | 0.00% | 0.0% |
| Q1 2022 | $75,695,000 | +5.3% | 2,162,096 | -2.5% | 0.00% | +33.3% |
| Q4 2021 | $71,883,000 | +12.7% | 2,217,248 | +2.6% | 0.00% | 0.0% |
| Q3 2021 | $63,772,000 | +90.1% | 2,161,772 | +65.1% | 0.00% | +50.0% |
| Q2 2021 | $33,550,000 | +162.2% | 1,309,519 | +40.5% | 0.00% | +100.0% |
| Q1 2021 | $12,798,000 | – | 932,136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |